COVID-19 Saliva-Based Detection Kits Market

COVID-19 Saliva-Based Detection Kits Market Outlook

Global demand for COVID-19 saliva-based detection kits experienced significant growth, with an estimated market value of around US$ 1.6 Bn in 2021. As per Fact.MR’s projections, PCR-based kits hold a substantial share of over 73% at present.

Key Insights Covered in COVID-19 Saliva-based Detection Kits Industry Survey:

• Market Estimates and Forecasts (2020-2031)
• Key Drivers and Restraints Shaping Market Growth
• Segment-wise, Country-wise, and Region-wise Analysis
• Competition Mapping and Benchmarking
• Market Share Analysis By Key Players
• Key Product Innovations and Regulatory Climate
• Recommendation on Key Winning Strategies

Sales Analysis of COVID-19 Saliva-based Detection Kits and Market Outlook for 2020 to 2031

Global demand for COVID-19 saliva-based detection kits expanded to reach a market value of US$ 1.4 Bn in 2020, as per Fact.MR, a market research and competitive intelligence provider.

The presence of COVID-19 virus mutants and ongoing risk of catching an infection are expected to drive demand for COVID-19 detection therapeutics. With increasing adoption of COVID-19 diagnostics, manufacturers are focused on providing cost-effective and convenient solutions for testing.

Until now, COVID-19 specimen collection was concentrated mainly on nasopharyngeal swabs that required trained personnel on invasive procedures. By the second quarter of 2020, sample collection options increased with the inclusion of self-collected samples such as saliva.

The U.S. FDA gave authorization for the use of OMNIgene® ORal from DNA Genotek's as a portion of its COVID-19 test kit. Since then, this product has been added to various diagnostic protocols, including at-home saliva collection for testing SARS-CoV-2. Such products also hold potential for COVID-19 mass testing in schools, colleges, universities, and other places for mass screening programs.

While the incidence rate in some countries may have come down due to rigorous vaccination programs, the virus still poses a great threat and reflects a high incidence rate due to mutant variants. Upcoming virus mutant strains and increased awareness of COVID-19 testing are expected to keep market growth consistent from 2026 to 2031, at a CAGR of 2.2%.

What are the Key Opportunities on Offer for COVID-19 Saliva-based Detection Product Manufacturers?

More cases of COVID-19 were observed post-lockdowns after 2-3 months of unlocking due to people not maintaining social distancing at public places. This made the diagnosis of COVID-19 mandatory in many countries.

Furthermore, to break the chain, people became more aware of COVID-19 therapeutic procedures and testing. Individuals who have very mild flu or cough symptoms also do detection tests. As such, demand for COVID-19 testing has increased. For demand fulfilment, RT-PCR is the best method to get a quick and accurate result for COVID-19 infection with the help of saliva.

Which Factors are Restraining Demand for COVID-19 Saliva-based Detection Kits?

The current market is powered by other specimens such as blood and nasopharyngeal swabs for detection. Saliva specimen is growing significantly owing to its convenience for both, self-detection and clinic use.

Despite this, many new players are launching kits where nasal swabs are used for testing, which is restraining market growth.

Country-wise Insights

What Makes the U.S. the Largest Market for COVID-19 Saliva-based Detection Kits?

The U.S. leads the North American region with a market share of 91%, and is projected to continue to do so throughout the forecast period. The U.S. population is focusing on adopting new technology for early detection of SARS-COV-2 Infection with the help of saliva.

The saliva method has various advantages such as cost-effectiveness and non-invasive feature. It has excellent stability and minimal risk of cross-infection. These factors are set to drive demand for COVID-19 saliva-based detection kits in the country.

Why is Italy Considered a Lucrative Market for COVID-19 Saliva-based Detection Kits in Europe?

Italy dominates the European market for COVID-19 saliva-based detection kits, with a share of 27% in 2021. This country is at high risk of a third wave, and people are at risk of getting infected and spreading COVID-19 variants.

Mutant variants have a high death rate, hence early detection can be helpful to control infection. That can be achieved by using rapid test kits. There is a huge opportunity for manufacturers to generate more revenue from Italy.

What is Majorly Driving the U.K. Market?

The U.K. dominates the European market for COVID-19 saliva-based detection kits, followed by Italy, with a share of 21% in 2021. Companies are focusing on the development of home-based diagnostic kits with CE marks. This makes testing easy for a patient at home itself.

For instance, in March 2021, Agilent Technologies received CE Mark for its kit with the PCR method, named the Agilent SARS-CoV-2 qRT-PCR Dx kit.

What Makes India an Emerging Market for COVID-19 Saliva-based Detection Kits?

India holds 13% share in the South Asia market. Demand is high due to increasing COVID-19 infection detection from diagnostic centres.

The outbreak of such a pandemic is a huge problem for India to meet patient demand for diagnosis and cure. Diagnostic centres were flooded with COVID-19 patients, with more cross-infection and spread of COVID-19 during the second wave. This can be minimised with saliva-based detection kits.

People are shifting to get their test results with less risk of cross-infection through self-detection kits. This can have a positive impact on the Indian market in the future.

What is the Outlook for China Regarding COVID-19 Saliva-based Detection Kits?

In 2021, China dominated the East Asia market with 89% share, due to the emergence of mutant variants.

Despite vaccination campaigns in China, majority of the population is yet to be vaccinated, and the vaccine is not potent for mutant variants. Hence, the emergence of a new variant first in China creates a pool of opportunities for local and leading players.

Category-wise Insights

Which COVID-19 Saliva-based Detection Kit Type is Driving Market Growth?

By product, PCR-based kits will lead the market with a share of 70% over the forecast period. High demand for these products is being seen due to increasing adoption of COVID-19 saliva-based detection kits.

PCR-based kits offer high sensitivity and specificity for the detection of SARS-CoV-2 coronavirus. Testing is also increasing due to high awareness about the self-detection of COVID-19.

Why is RT-qPCR Highly Used for COVID-19 Saliva-based Detection?

RT-qPCR dominates the market with 49% revenue. This trend is expected to continue during the study period. High share of this segment is attributed to growing demand for point-of-care testing (POCT).

Real-time diagnoses are rapid results (differs according to the test). They also diagnose current or detect past SARS-CoV-2 infections in various healthcare settings, which, in turn, is driving demand.

What is the Impact of COVID-19 on the Industry?

The COVID-19 pandemic has led to an upsurge in the demand for COVID-19 testing. Furthermore, there is the occurrence of the second wave in certain countries in the last two quarters and the anticipated outbreak of second and third waves across different countries.

Therefore, it can be rightly assumed that COVID-19 saliva-based detection kits will experience further demand growth over the coming years.

What is the Impact of Market Consolidation on the COVID-19 Saliva-based Detection Kits Business Space?

Considering consolation activities in the global market, mergers and acquisitions have emerged as one of the key growth strategies by market players. Prominent players are strengthening their product ranges for getting approvals from various authorities and reaching out to key as well as emerging markets.

• For instance, in April 2021, Chembio Diagnostics, Inc. announced the launch of a U.S. FDA approved rapid POCT for COVID-19/Flu A&B test.

Competitive Landscape

Key players are focusing on expansion in emerging regions and new revised product manufacturing. The strategy of acquisition and collaborations by key manufacturers is further strengthening their market presence.

• For instance, in January 2021, Thermo Fisher Scientific acquired Mesa Biotech, a developer of hand-held test devices for COVID-19 detection. This acquisition enabled Thermo Fisher Scientific to accelerate the availability of reliable and accurate advanced molecular diagnostics at the POCT.
• Similarly, recent developments related to companies manufacturing COVID-19 saliva-based detection kits have been tracked by the team at Fact.MR, which are available in the full report.

Report Scope as per COVID-19 Saliva-based Detection Kits Industry Analysis

Attribute	Details
Market size value in 2021	USD 1.6 Billion
Market forecast value in 2031	USD 1.2 Billion
Growth Rate	CAGR of -2.8% from 2021 to 2031
Forecast Period	2021-2031
Market Analysis	US$ Mn for Value
Key Regions Covered	North America Latin America Europe South Asia East Asia Oceania  Middle East & Africa
Key Countries Covered	US Canada Brazil Mexico Germany U.K. France Italy Spain Benelux Russia China Japan South Korea India Thailand Indonesia Malaysia Singapore China Japan South Korea Australia New Zealand Turkey Egypt North Africa South Africa GCC Countries
Key Market Segments Covered	Product Technology Application End User Region
Key Companies Profiled	Thermo Fisher Scientific Inc Qiagen Hologic Takara Bio Inc Arcis Biotechnology Limited GeneProof Abacus ALS Kolplast Group Vitagene Therma Bright Inc ACON Laboratories, Inc Assure Tech. (Hangzhou) Co., Ltd KYODO INTERNATIONAL INC. Zymo Research Corporation. Salimetrics
Pricing	Available upon Request

Key Segments Covered in COVID-19 Saliva-based Detection Kits Industry Research

• By Product

  • Rapid Test Kits
  • PCR-based Kits

• By Technology

  • Direct Sample to PCR
  • RT-qPCR
  • Lateral Flow Assays

• By Application

  • COVID-19 Research
  • COVID-19 Diagnostics

• By End User

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Academic and Research Institutes
  • Biopharma  Companies
  • Long Term Care Facilities
  • Home Care Settings
  • Others